Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05797584
Other study ID # 09C923
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 20, 2019
Est. completion date March 20, 2026

Study information

Verified date March 2023
Source Istituto Auxologico Italiano
Contact Sergio Caravita, MD, PhD
Phone +390261911
Email s.caravita@auxologico.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Right ventricle dysfunction and pulmonary hypertension are related to a worse prognosis in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) or with normal left ventricular ejection fraction (HFpEF). There is preliminary evidence however, that the responses of the right ventricle and of the pulmonary hemodynamics to stress tests (especially physical stress) may allow to prognostically stratify these patients, as these responses may bring out latent right ventricle dysfunction or a normal contractile reserve in patients with dysfunction at rest. In view of the different pathophysiological mechanisms of the left ventricular dysfunction in HFpEF and in HFrEF, also the response and the adaptation of the righty ventricle to stress tests may be different in these two groups of patients. In this preliminary two groups of 20 patients with HFpEF and HFrEF will be subjected to to simple stress tests: passive leg raising and inotropic stimulus with dobutamine. This study intends to analyze, through colorDoppler echocardiography, the behaviour of the right ventricle and the pulmonary circulation during passive leg raining and infusion of dobutamine, in a cohort of patients with HFrEF or HFpEF. The analysis will be focused on the relation between echocardiographic parameters, especially those concerning right ventricular function and pulmonary hemodynamics, thereby comparing the responses observed in HFrEF vs HFpEF. Furthermore, correlations between the above-mentioned echocardiographic parameters and parameters of daily clinical practice will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 20, 2026
Est. primary completion date March 20, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - heart failure with reduced (EF =40%) or preserved (EF > 50%) ejection fraction - echocardiographic acoustic window adequate for evaluation of outcome parameters - presence of tricuspid insufficiency which allows assessment of pulmonary artery systolic pressure Exclusion Criteria: - recent myocardial infraction (<3 months) or unstable angina - moderate o severe aortic or mitralic valve disease - inadequate acoustic window - significant anemia (hemoglobin <10 g/dl) - recent heart surgery (< 3 months).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dobutamine
Dobutamine 5.0 - 10.0 mcg/Kg/min ev
Other:
Passive leg raising
Passive leg raising for acute volume load

Locations

Country Name City State
Italy Ospedale San Luca IRCCS Istituto Auxologico Italiano Milan MI

Sponsors (1)

Lead Sponsor Collaborator
Istituto Auxologico Italiano

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Right ventricle (RV) volume - Dobutamine Change in RV volume Baseline and at 5 minutes after Dobutamine infusion
Primary Ejection fraction - Dobutamine Change in ejection fraction Baseline and at 5 minutes after Dobutamine infusion
Primary Right ventricle (RV) volume - Passive leg raining Change in RV volume Baseline and at 1 minute after passive leg raising for acute volume load
Primary Ejection fraction - Passive leg raining Change in ejection fraction Baseline and at 1 minute after passive leg raising for acute volume load
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy